Following on from information provided to NICE by the company in October 2017, the appraisal of Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1250 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in October 2017, the appraisal of Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 18 October 2017 | Suspended. The company have advised that they will not be pursuing a licensing application for vemurafenib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. |
| 18 October 2017 | The company have advised that they will not be pursuing a licensing application for vemurafenib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. |
| 29 August 2017 - 26 September 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 28 August 2017 | Draft scope documents |
| 19 September 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual